1. Home
  2. GWRS vs ANIK Comparison

GWRS vs ANIK Comparison

Compare GWRS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Water Resources Inc.

GWRS

Global Water Resources Inc.

HOLD

Current Price

$7.06

Market Cap

214.3M

Sector

Utilities

ML Signal

HOLD

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

HOLD

Current Price

$14.58

Market Cap

197.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GWRS
ANIK
Founded
2003
1983
Country
United States
United States
Employees
N/A
235
Industry
Water Supply
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.3M
197.6M
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
GWRS
ANIK
Price
$7.06
$14.58
Analyst Decision
Hold
Buy
Analyst Count
1
1
Target Price
$9.20
$17.00
AVG Volume (30 Days)
51.5K
116.4K
Earning Date
05-13-2026
04-29-2026
Dividend Yield
4.22%
N/A
EPS Growth
N/A
80.16
EPS
0.11
N/A
Revenue
$41,914,000.00
$112,819,000.00
Revenue This Year
$15.29
$5.98
Revenue Next Year
$8.28
$7.42
P/E Ratio
$64.55
N/A
Revenue Growth
8.51
N/A
52 Week Low
$7.07
$7.90
52 Week High
$11.17
$16.24

Technical Indicators

Market Signals
Indicator
GWRS
ANIK
Relative Strength Index (RSI) 32.09 49.53
Support Level N/A $13.81
Resistance Level $7.82 $15.01
Average True Range (ATR) 0.17 0.92
MACD -0.03 -0.23
Stochastic Oscillator 1.92 60.19

Price Performance

Historical Comparison
GWRS
ANIK

About GWRS Global Water Resources Inc.

Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix and Tucson, Arizona. It operates within the State of Arizona. Operating revenue of the company is derived from regulated water, wastewater, and recycled water service provided to customers based upon tariff rates.

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Share on Social Networks: